Osmotica Pharmaceuticals (NASDAQ:OSMT) Raised to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

A number of other equities research analysts have also weighed in on the stock. Barclays reaffirmed a hold rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. Wells Fargo & Co set a $14.00 target price on shares of Osmotica Pharmaceuticals and gave the company a buy rating in a research note on Thursday, March 28th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $14.00.

Shares of OSMT traded down $0.06 during trading hours on Tuesday, reaching $3.56. 105 shares of the company traded hands, compared to its average volume of 139,424. The firm has a fifty day moving average price of $3.25. The stock has a market cap of $185.48 million and a P/E ratio of -7.08. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.70 and a quick ratio of 1.41. Osmotica Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $9.90.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). The firm had revenue of $57.13 million for the quarter, compared to analysts’ expectations of $53.58 million. Equities analysts anticipate that Osmotica Pharmaceuticals will post -0.25 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new stake in Osmotica Pharmaceuticals during the first quarter worth about $45,000. American International Group Inc. bought a new stake in Osmotica Pharmaceuticals during the fourth quarter worth about $50,000. Deutsche Bank AG bought a new stake in Osmotica Pharmaceuticals during the fourth quarter worth about $111,000. Northern Trust Corp bought a new stake in Osmotica Pharmaceuticals during the fourth quarter worth about $615,000. Finally, Geode Capital Management LLC bought a new stake in Osmotica Pharmaceuticals during the fourth quarter worth about $668,000. 11.64% of the stock is currently owned by institutional investors and hedge funds.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

See Also: Strike Price

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit